Robert J. Mylod Jr. has been a director of Novocure since 2012, serving on our audit committee since 2012 and on our nominating and corporate governance committee since 2015. Mr. Mylod has served as managing member of Annox Capital LLC, a private investment firm, since 2012. From 2009 to 2011, Mr. Mylod served as Vice Chairman and Head of Worldwide Strategy and Planning at priceline.com. Prior to being named Vice Chairman, Mr. Mylod served as priceline.com’s Chief Financial Officer from November 2000. Before joining priceline.com, Mr. Mylod was a Principal at Stonington Partners, a private equity investment firm. Mr. Mylod also serves on the board of EverBank Financial Corp. and of Autobytel, Inc. Mr. Mylod earned an A.B. in English from the University of Michigan and an M.B.A. from the University of Chicago Graduate School of Business.
novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma and mesothelioma. Novocure has ongoing or completed clinical trials investigating our therapy in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.